Ultrashort chain per- and polyfluoroalkyl substances (USC-PFAS),defined as those with three or fewer carbon atoms, are characterisedby their significant mobility within the environment, high water solubility,and low affinity for organic matter. These properties contributeto their widespread presence in environmental waters and wastewaters,as well as drinking waters. The environmental concerns associatedwith USC-PFAS include their persistence, potential for groundwatercontamination, and challenges in remediation due to their resistance to conventional treatment methods.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ALS_Czech_Republic_Enviromail_29_Unstoppable_Ultrashort_PFAS_in_the_environment_and_water_sources_2_093d51b263.jpg" alt="EnviroMail™29/Europe: Unstoppable? Ultrashort PFAS in the environment and water sources: Figure 1: Illustrative picture" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ALS_Czech_Republic_Enviromail_29_Unstoppable_Ultrashort_PFAS_in_the_environment_and_water_sources_2_093d51b263.jpg 245w," sizes="100vw" width="602" height="247"><h4>Occurence, uses and sources</h4>Ultrashort chain PFAS have been poorly characterised compared with their longer chain counterparts, and understanding of their intended and unintended transformation processes is limited. Sources of USCPFAS include degradation of precursor compounds, atmospheric degradation of hydrofluorocarbons and hydrochlorofluorocarbons used as refrigerants, and intentional direct use in products like batteries. Crucially, TFA, a major ultrashort-chain PFAS, is also formed through the environmental breakdown of fluorinated pesticides and pharmaceuticals. They are also byproducts from historical electrochemical fluorination (ECF) manufacture of longer chain PFAS. USC-PFAS are also found in urban and industrial waste, as well as aqueous film-forming foams (AFFFs) used in firefighting.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ALS_Czech_Republic_Enviromail_29_Unstoppable_Ultrashort_PFAS_in_the_environment_and_water_sources_5698c634d6.jpg" alt="EnviroMail™29/Europe: Unstoppable? Ultrashort PFAS in the environment and water sources: Figure 2: PFSA and PFCA categorization based on carbon chain length – ultrashort-chain, short-chain and long-chain." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ALS_Czech_Republic_Enviromail_29_Unstoppable_Ultrashort_PFAS_in_the_environment_and_water_sources_5698c634d6.jpg 245w," sizes="100vw" width="1496" height="629"><h4>Fate and transport</h4>Carbon chain length plays a key role in determining the physicochemical characteristics of different PFAS chemicals. Long chain PFAS for instance are more hydrophobic, a property that has been leveraged by removal techniques using carbonaceous materials like granular activated carbon (GAC). By contrast, short and ultrashort chain PFAS are hydrophilic, with characteristically low pKa values (i.e. more acidic), high water solubilities and decreased log Koc values (i.e. less adsorptive to organic carbon). These attributes mean that USC-PFAS dissociate freely in aqueous environments and are less prone to sorption onto natural solids. The outcome is that USCPFAS are highly mobile in the aquatic environment and can travel far from contamination source areas.<h4>The global regulatory landscape</h4>Awareness about the persistence and bioaccumulative nature of C8-C14 PFAS began to attract widespread concern near the turn of the millennium, and inclusion of PFOS, PFOA and PFHxS on the persistent organic pollutants (POPs) list of the Stockholm Convention soon ensued. Consequentially, manufacturers began adopting short and ultrashort chain alternatives.However, with the change from C8 to C4 and shorter fluorinated carbon chains came the sacrifice to lower technical performance, and greater quantities were needed for equivalent performance. Hence, while it is generally accepted that short and ultrashort chain PFAS have lower toxicological profiles, environmental risks are not necessarily obviated since USC-PFAS presence, and continuous, cumulative, release suggests that adverse risks may lie ahead.Global regulations of USC-PFAS vary by region and are often included under broader PFAS regulations. For example, the European Union has specific guidelines and limits for the total concentration of PFAS compounds in drinking water (as set out in EU Directive 2020/2184). The EU's Drinking Water Directive established a limit of 0.5 μg/L for 'PFAS Total,' although ongoing discussions concern the specific methodology for incorporating trifluoroacetic acid (TFA). Furthermore, TFA was recently added to the priority list for the initial proposed sum of 24 PFAS in surface water. <a target="_blank" rel="noopener noreferrer" href="https://www.consilium.europa.eu/en/press/press-releases/2025/09/23/water-pollution-council-and-parliament-reach-provisional-deal-to-update-priority-substances-in-surface-and-ground-waters/">LINK</a><h4>PFAS sampling containers</h4>Only tested and verified sampling containers are recommended to ensure reliable results in PFAS analysis; these containers are available upon request from ALS laboratories.<h4>Targeted analytical services are becoming more accessible</h4>Testing for USC-PFAS is challenging due to several analytical factors. Background contamination and matrix noise can interfere with the detection of these compounds, particularly trifluoroacetic acid (TFA). Furthermore, sample preparation presents a significant challenge because of the constant risk of cross-contamination. To mitigate this risk, the sample preparation procedure was specifically designed to be as simple and straightforward as possible.Other USC-PFAS compounds generally have lower ambient background concentrations, which makes achieving lower Limits of Reporting (LOR) more readily achievable. ALS has successfully developed a testing method that includes USC-PFAS compounds in environmental water matrices, achieving a total LOR of 50 ng/L for TFA and even lower LORs for other USC compounds. The full list of analyzed USC-PFAS is summarized in table 1:<h5>USC-PFAS Compounds / CAS No.</h5><ul><li>Trifluoroacetic acid (TFA), Perfluoroethanoic acid (PFEtA): 76-05-1</li><li>Trifluoromethane sulfonic acid (TFMS), Perfluoromethane sulfonic acid (PFMeS): 1493-13-6</li><li>Perfluoroethane sulfonic acid (PFEtS): 354-88-1</li><li>Perfluoropropanoic acid (PFPrA): 422-64-0</li><li>Perfluoropropane sulfonic acid (PFPrS): 423-41-6</li><li>Trifluoromethane sulfinic acid: 34642-42-7</li><li>Lithium bis(trifluoromethanesulfonyl)imide (LiTFSI): 90076-65-6</li></ul>&nbsp;

EnviroMail™29/Europe: Unstoppable? Ultrashort PFAS in the environment and water sources

<h4>Why Consider HILIC in Modern Oligonucleotide Analysis?</h4>Oligonucleotides play a central role in gene therapies, molecular diagnostics, and cutting-edge biomedical research. Before these molecules reach application, however, they must be carefully characterized to confirm purity, identity, and performance.Analyzing therapeutic oligonucleotides is far from straightforward. Their polarity, structural diversity, and modifications demand highly selective and MS-compatible separation methods. Although ion-pair reversed-phase LC (IP-RP-LC) remains the established standard for LC-MS workflows, hydrophilic interaction liquid chromatography (HILIC) is rapidly emerging as a powerful complementary technique.When IP-RP approaches reach practical or performance limits, HILIC offers an attractive alternative, delivering strong retention and efficient separation of highly polar oligonucleotides — without relying on ion-pairing reagents.<h4>How Does HILIC Separate Oligonucleotides?</h4>HILIC essentially reverses conventional reversed-phase logic. It combines:<ul><li>A polar stationary phase</li><li>An organic-rich mobile phase</li></ul>In this configuration, the stationary phase retains a thin, water-enriched layer on its surface. Polar analytes — such as oligonucleotides — partition into this aqueous layer while the acetonitrile-rich mobile phase passes through.This mechanism allows:<ul><li>Retention of short or highly polar oligonucleotides</li><li>Separation of modified sequences</li><li>LC-MS compatibility without ion-pairing reagents</li></ul>The key to performance lies in carefully tuning the parameters that govern HILIC selectivity and retention.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_1_Key_Parameter_of_HILIC_Mode_fb364c9a8b.webp" alt="KNAUER: Figure 1 - Key Parameter of HILIC Mode." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_1_Key_Parameter_of_HILIC_Mode_fb364c9a8b.webp 245w," sizes="100vw" width="945" height="433"><h4>What Controls Retention in HILIC?</h4>Several interaction mechanisms contribute to analyte behavior in HILIC:<h5>Hydrophilic Partitioning – The Primary Mechanism</h5>Polar molecules distribute into the thin water layer formed on the stationary phase surface. The greater the polarity of the analyte, the stronger its affinity for this layer, leading to increased retention.<h5>Hydrogen Bonding – Fine-Tuning Effects</h5>Functional groups such as –OH, –NH₂, and –COOH can form hydrogen bonds with the stationary phase, subtly influencing retention time and selectivity.<h5>Electrostatic Contributions – The Role of Charge</h5>Some HILIC materials (e.g., bare silica) exhibit surface charges. Depending on mobile phase pH and buffer composition, electrostatic interactions can either enhance or suppress analyte retention.<h5>Dipole and Ion–Dipole Interactions – Added Selectivity</h5>Highly polar or zwitterionic compounds — including phosphorylated species and sugars — may engage in dipole–dipole or ion–dipole interactions, further refining separation behavior.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_2_Hydrophilic_Partitioning_on_Water_enriched_Layer_41ab9ac902.webp" alt="KNAUER: Figure 2 - Hydrophilic Partitioning on Water-enriched Layer." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_2_Hydrophilic_Partitioning_on_Water_enriched_Layer_41ab9ac902.webp 245w," sizes="100vw" width="945" height="409"><h4>How to Develop a HILIC Method for Oligonucleotides</h4>Like any chromatographic method, successful HILIC development follows a structured approach:<h5>Step 1: Define the Analytes</h5>Understand oligonucleotide length, polarity, charge, and modifications.<h5>Step 2: Select a Suitable Column</h5>Choose a polar stationary phase (e.g., amide or zwitterionic) appropriate for the oligonucleotide’s chemical properties.<h5>Step 3: Optimize the Mobile Phase</h5><ul><li>Start with 70–95% acetonitrile</li><li>Use a volatile buffer (e.g., ammonium formate or ammonium acetate, typically 5–20 mM)</li><li>Adjust pH (commonly between 6–8, with testing up to pH 9 if column stability allows)</li></ul>Small pH shifts can significantly alter selectivity and MS response.<h5>Step 4: Design the Gradient</h5>Employ a gradient that increases water content to modulate retention and separate oligonucleotides by size or chemical modification.<h5>Step 5: Match Injection Conditions</h5>Samples should be injected in a solvent similar to the starting mobile phase (high organic content) to prevent peak distortion.<h5>Step 6: Evaluate Performance</h5>Assess:<ul><li>Resolution</li><li>Retention time stability</li><li>Peak shape</li><li>Reproducibility</li></ul>Balancing separation performance with MS ionization efficiency is essential.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Table_1_HILIC_Method_Step_Procedure_for_Oligos_f3b9ea6b08.webp" alt="KNAUER: Table 1 - HILIC Method Step Procedure for Oligos." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Table_1_HILIC_Method_Step_Procedure_for_Oligos_f3b9ea6b08.webp 245w," sizes="100vw" width="945" height="357"><h4>Practical Tips for High-Performance HILIC</h4><h5>Maintain a Stable Water Layer</h5>A minimum of ~5% water is necessary at the start of the run. Too little water can eliminate retention entirely. Adjust water content carefully to fine-tune retention.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Figure_3_Water_Adjustment_Principle_for_HILIC_c0d8616f20.webp" alt="KNAUER: Figure 3 - Water Adjustment Principle for HILIC." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Figure_3_Water_Adjustment_Principle_for_HILIC_c0d8616f20.webp 245w," sizes="100vw" width="951" height="374"><h5>Use High Organic Content</h5>HILIC typically operates best with 70–95% acetonitrile. Polar analytes are retained more effectively under these conditions.<h5>Include a Volatile Buffer</h5>Use low concentrations (5–20 mM) of ammonium formate or acetate to:<ul><li>Stabilize pH</li><li>Reduce peak tailing</li><li>Maintain MS compatibility</li></ul><h5>Control Injection Solvent</h5>Avoid high-water sample solvents. They disrupt the partitioning mechanism and distort peaks.<h5>Allow Proper Column Equilibration</h5>HILIC columns require longer equilibration times than reversed-phase columns — typically 10–20 column volumes after major gradient or solvent changes.<h5>Consider Temperature</h5>Operating at 30–50 °C can:<ul><li>Improve peak shape</li><li>Reduce mobile phase viscosity</li><li>Stabilize retention behavior</li></ul><h4>From Alternative to Essential? Final Perspective</h4>HILIC-MS is steadily advancing as a strong, ion-pair-free option for oligonucleotide analysis. While IP-RP-LC still dominates in sensitivity for many applications, HILIC is closing the gap and offering valuable flexibility — particularly for highly polar or challenging sequences.Although HILIC follows different chromatographic principles than reversed-phase separations, once optimized, it can deliver robust and highly selective results.Rather than being a niche method, HILIC is becoming a strategic tool in modern oligonucleotide workflows — especially when MS compatibility and method versatility are priorities.If you are developing or refining an oligonucleotide LC-MS method, HILIC may be worth integrating into your analytical toolbox.<blockquote><ul><li>For additional information or discussion, feel free to contact: <a>sales@knauer.net<svg><use></use></svg></a></li><li>For direct scientific inquiries, reach out to the author at: <a>kindler@knauer.net<svg><use></use></svg></a></li></ul></blockquote>Stay tuned for more insights in the “Oligos Made Easy” series.

Oligos Made Easy - Part 4: HILIC

News from LabRulezLCMS Library - Week 09, 2026

Article

Application

Academy

Environment

Science and research

Poster

For more than 40 years, ALS has provided testing and technical solutions to clients all over the world in a wide range of industries. We have built our global reputation by embracing the latest technologies and innovative methodologies to deliver high quality testing services to clients. ALS is able to leverage a multifaceted international team while remaining agile enough to provide local expertise and personalized solutions to every one of our clients.

ALS Czech Republic

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

Tosoh Bioscience

Separation Science

The Analytical Scientist

Agilent Technologies

Waters Corporation

What is peptide mapping? How many types of post-translational modifications can be analyzed?
Access the most detailed information at the intact protein level, automatically confirm protein sequence at the peptide level, and confidently understand post-translational modifications. Attend this episode premiere to decode peptides and to know more about the same.
<blockquote>
Presenter: Dr. Ashish Pargaonkar (Lead for Biopharma Workflow Commercialization, Agilent Technologies)
</blockquote>
<blockquote>
Presenter: Ms. Paramjeet Khandpur (Biopharma Workflow Commercialization Lead, Agilent Techologies)
</blockquote>

Agilent Technologies: Peptide Mapping: Decoded

Peptide Mapping: Decoded

What is peptide mapping? How many types of post-translational modifications can be analyzed?

From beginner to expert, we can all benefit from a review of HPLC basics. In this two-part talk, we will work our way from basic chromatographic principles to advanced method development topics.
In Method Development 101, we will cover such fundamentals as partitioning, retention factor, selectivity, and resolution. After a quick review of these basics, we seek to better understand the resolution equation and what it tells us about establishing or changing method conditions. We will also discuss how the physical/chemical properties of our analytes impact our choice of column chemistries.
<blockquote>
Presenter: Melissa Goodlad (Application Engineer, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Melissa Goodlad is an Application Engineer providing applications assistance and technical support for Agilent’s HPLC columns and consumables. Before joining Agilent, Melissa was completing her PhD in Physical Chemistry at UC Merced studying nanoparticle self-assemblies.
</blockquote>

Agilent Technologies: HPLC Method Development: From Beginner to Expert, Part 1

HPLC Method Development: From Beginner to Expert, Part 1

Basic chromatographic principles to advanced method development topics.

Vitamin D is an essential nutrient with several biological functions including immune system regulation and calcium absorption. Caffeine-free rooibos tea is an ideal carrier for vitamin D3 supplementation because of its health benefits. It is also a potential base for the addition of Saskatoon berry syrup, a natural flavor additive.
This webinar highlights the development of an iced-rooibos tea with Vitamin D3 and Saskatoon berry syrup fortification as a functional beverage. Sensory evaluation by consumer acceptability and determination of antioxidant properties by LC-QTOF MS will also be discussed.
<h3>Key Learning Objectives/What attendees will learn:</h3>
<ul>
<li>An introduction on Functional Foods/Beverages and Their Importance to Nutrition and Health
</li>
<li>Consumer Acceptability and Descriptive Studies
</li>
<li>Determination of Functionality of the Developed Beverage
</li>
</ul>
<h5>Who Should Attend:</h5>
Researchers and food developers with an interest in functional foods and beverages and/or flavor chemistry and sensory studies
<blockquote>
Presenter: Michel Aliani (Professor, University of Manitoba)
</blockquote>
<blockquote>
Michel Aliani is a Professor at the Department of Food and Human Nutritional Sciences, University of Manitoba. His area of scientific expertise includes food science, physiology, mass spectrometry (MS), and Nuclear Magnetic Resonance (NMR)-based metabolomics.
</blockquote>
<blockquote>
Research focus and interests:
<ol>
<li>To provide the scientific and molecular basis for the development and successful marketing of functional foods destined for patients with chronic diseases as well as healthy populations in the world and,</li>
<li>To investigate the effect of active compounds on metabolic pathways in animal and human models.</li>
</ol>
</blockquote>

Agilent: Acceptability and Antioxidant Properties of Vit D and Saskatoon Berry Fortified Rooibos Tea

Acceptability and Antioxidant Properties of Vit D and Saskatoon Berry Fortified Rooibos Tea

This webinar highlights the development of an iced-rooibos tea with Vitamin D3 and Saskatoon berry syrup fortification as a functional beverage

Vit D and Saskatoon Berry Fortified Rooibos Tea

Per-and polyfluoroalkyl substance (PFAS) testing has evolved rapidly in the past decade due to the severe health risks related to human exposure. As we expand our understanding of the prevalence of these toxic compounds, analytical laboratories must develop workflows to handle more challenging matrices.
This webinar demonstrates a homogenization, extraction, and concentration workflow that provides exceptional precision, accuracy, and detection limits for PFAS in fish tissue samples. In addition, we discuss how to overcome some of the challenges associated with PFAS extraction and determination by isotope dilution or extracted internal standard quantification. Through this collaborative effort, we are thrilled to introduce a new simplified and automated sample preparation workflow applicable to testing for PFAS in solid samples.
<h5>By attending this presentation, you will learn:</h5>
<ul>
<li>How to simplify your lab&#39;s sample preparation workflows by eliminating manual transfer steps when processing samples for PFAS analysis.</li>
<li>Tips for optimizing sample preparation and analytical performance to make sample analysis easier, more accurate, and more reliable.</li>
</ul>
<h5>Who Should Attend:</h5>
<ul>
<li>Analytical laboratories performing PFAS analysis</li>
<li>Laboratories testing tissue, soils, and biosolid samples</li>
<li>Sample preparation, extraction, and analytical chemists</li>
<li>Laboratories performing liquid chromatography-mass spectrometry (LC-MS/MS)</li>
</ul>
<blockquote>
Presenter: Lauren Dreyling (Chemist at the Indiana Department of Health)
</blockquote>
<blockquote>
Lauren has worked for the Indiana Department of Health (IDOH) in a variety of roles for over nine years. Her most recent role is in the Chemical Threat/Opioid Surveillance lab working for the past five years on a variety of methods for LC-MS/MS, GC-MS, and LC-ICP-MS. She also takes an active role in method development for LC-MS/MS, LC-QTOF, and GC-MS/MS for a variety of matrices; both clinical and environmental. Lauren has been at the head of all PFAS method development (537.1, 533, and 1633) for IDOH since 2020.
</blockquote>
<blockquote>
Presenter: Evan Walters (Evan Walters (MSc), Market Segment Manager, Biotage)
</blockquote>
<blockquote>
Evan Walters is passionate about science and analytical chemistry in environmental, food and agriculture markets. A trained environmental chemist and geochemist, Evan uses his background in analytical chemistry to connect laboratories with products and workflow solutions to ensure their success. Evan received a Master of Science in Geochemistry from Southern Illinois University and is a published scientific author.
</blockquote>

Separation Science: Optimization of PFAS analysis in fish tissue samples through a simplified and automated sample preparation workflow

Optimization of PFAS analysis in fish tissue samples through a simplified and automated sample preparation workflow

This webinar demonstrates a homogenization, extraction, and concentration workflow for PFAS in fish tissue samples.

Optimization of PFAS analysis in fish tissue samples

<h3>Solving Problems That Matter - a Waters webinar series featuring USP speakers</h3>
<h3>Episode 1: USP 621 Harmonization - Method Scaling</h3>
Summary
On December 1, 2022 a harmonized standard for General Chapter &lt;621&gt; Chromatography was released. This standard incorporates the USP with 2.2.46. Chromatographic Separation Techniques European Pharmacopoeia (EuPh) and 2.01 Liquid Chromatography Japanese Pharmacopeia (JP) texts. Harmonization of these regulatory guidance provides increased method flexibility through the employment of modernized of chromatographic tools without the need for full monograph re-validation.
Key Learning Objective: Learn how to modernize your LC system and reduce operation costs using the USP &lt;621&gt; allowable adjustments.
Who Should Attend: Scientists and lab managers involved with compendial methods with a drive towards modernization, productivity and compliance.
<blockquote>
Presenter: Amanda Guiraldelli, Ph.D. (Scientific Affairs Manager, U.S. Pharmacopoeia)
</blockquote>
<blockquote>
Amanda Guiraldelli has been with USP since 2012 and holds the position of scientific affairs manager and principle scientist in the compendial science group-general chapters. She also serves as scientific liaison for the USP Measurement and Data Quality Expert Committee, where she works to develop and revise USP standards related to analytical procedure lifecycle/validation. Previously, Amanda worked as senior scientist at the USP reference standard laboratory for 8 years with characterization of compendial standards. She is visiting professor at the Institute of Chemistry at the University of Campinas (UNICAMP) in Brazil and is a frequent speaker and instructor on topics related to analytical procedure life cycle, Analytical Quality by Design (AQbD) and Chromatography. Amanda is specialist in mass spectrometry, chromatography, omics and chemometrics and has more than 15 years of experience in pharmaceutical R&amp;D areas. Prior to joining USP, she was R&amp;D scientist in a brazilian pharmaceutical industry and visiting scientist at TU Berlin in Germany and Leiden University in Netherlands (Center for Proteomics and Metabolomics) working on proteins characterization by LC-HRMS and procedure development using UHPLC-HRMS. Amanda is graduated in pharmacy biochemistry and holds a Ph.D. in analytical chemistry from the FCFRP - University of São Paulo (metabolomics by UHPLC-HRMS, GC-MS and 1H NMR and chemometrics).
</blockquote>
<blockquote>
Presenter: Catharine Layton (Principal Scientist, Scientific Operations, Waters Corporation)
</blockquote>
<blockquote>
Catharine is a Principal Scientist on the QA-QC Team at Waters Corporation located in Milford, MA. She works closely with technical experts to develop and provide the appropriate instrumentation and methodology for laboratories throughout the world. She began her career in Biopharmaceutical Development R&amp;D at a fast paced, contract research organization and drug development laboratory where she was responsible for the design of analytical methods used to characterize novel biological therapeutics formulated by key research organizations. Catharine later moved into large pharma and analytical instrument development, where she has dedicated many years to the advancement and implementation of analytical testing strategies and methodology.
</blockquote>
<blockquote>
Moderated by: Isabelle Vu Trieu (Pharmaceutical Market Development Manager, Americas, Waters Corporation)
</blockquote>
<blockquote>
Isabelle is a business development professional dedicated to delivering benefits to analytical scientists in the life sciences industry. With over 20 years of experience in providing chromatography and mass spectrometry solutions, Isabelle is particularly interested in helping pharmaceutical scientists achieve the data quality and integrity needed to drive decisions for drug quality, safety and efficacy. Isabelle joined Waters in 2009 and currently manages the development of the pharmaceutical market in the Americas. She holds Masters’ degrees in Chemistry from Columbia University and the University Claude Bernard in Lyon, France as well as a Chemical Engineering degree from Ecole Supérieure de Chimie Physique Electronique in Lyon, France.
</blockquote>

Waters Corporation: Solving Problems That Matter - a Waters webinar series featuring USP speakers

USP 621 Harmonization - Method Scaling

Learn how to modernize your LC system and reduce operation costs using the USP <621> allowable adjustments.

Episode 1: USP 621 Harmonization - Method Scaling

Size exclusion chromatography (SEC) is a well-established analytical method for quantitative and qualitative aggregate analysis of monoclonal antibodies (mAbs) and other related biotherapeutics. However, because SEC is a non-adsorptive separation modality, it may be unclear as to which method parameters to adjust for the optimal separation of monomer, aggregate, and fragment.
In this presentation, we discuss SEC method experimental design space. Column selection, mobile phase, flowrate, and injection volume are all discussed to ensure optimal separation of monomer, aggregate, and fragment of mAbs and other mAb formats.
Webinar Learning Objectives:
<ul>
<li>Learn about a breakthrough in SEC column development to improve method robustness for monoclonal antibodies and related recombinant proteins</li>
<li>Understand how column choice‑including exclusion limit, particle size, and column length may affect chromatographic performance</li>
<li>Determine a practical mobile phase screen to optimize mAb aggregate recovery, fragment separation and understand when organic solvent should be used and how other co-solvents may be beneficial in improving peak shape and recovery</li>
</ul>
<blockquote>
Presenter: Helen Whitby, PhD (Senior Product Manager – Biopharma, Phenomenex)
</blockquote>
<blockquote>
Helen has a PhD in synthetic organic and analytical chemistry from the University of Manchester, UK and has worked at Phenomenex for the last 15 years specialising in HPLC and Bioseparations.
</blockquote>

Phenomenex: Method Robustness and Transferability for Modern Size-Exclusion Methods

Method Robustness and Transferability for Modern Size-Exclusion Methods

We discuss SEC method experimental design space. Column selection, mobile phase, flowrate, and injection volume are all discussed

Method Robustness and Transferability for Modern SEC Methods

As the pipeline for synthetic oligonucleotide therapeutics continues to expand and diversify, the challenge of obtaining robust bioanalytical data efficiently has become more pronounced with sample prep representing the most significant source of variability.
To address this challenge Waters recently introduced automation-friendly OligoWorks SPE (Solid Phase Extraction) Kits to facilitate oligonucleotide extraction from biological samples for quantitative LC-MS analysis.
In this webinar, Waters application development scientists will present new HRMS full scan data on plasma samples, as well as HRMS and Tandem Quad data from liver samples, and discuss method variables that can be optimized to achieve higher recoveries.
Key learnings:
<ul>
<li>How OligoWorks SPE sorbent is tested and qualified for oligonucleotide recovery</li>
<li>Optimization parameters for HRMS/ MSe data capture and analysis</li>
<li>Tissue processing procedure and optimization parameters to maximize recovery and eliminate clogging</li>
</ul>
<blockquote>
Presenter: Nikunj Tanna (Principal Scientist, Scientific Operations, Waters Corporation)
</blockquote>
<blockquote>
Presenter: Makda Araya (Senior Scientist - Evaluation and Application Science, Waters Corporation)
</blockquote>
<blockquote>
Moderator: Joe Fredette (Principal Product Marketing Manager, Waters Corporation)
</blockquote>

Waters Corporation: Therapeutic Oligonucleotide Analysis from Plasma & Tissues Samples using OligoWorks SPE Kits

Therapeutic Oligonucleotide Analysis from Plasma & Tissues Samples using OligoWorks SPE Kits

New HRMS full scan data on plasma samples, as well as HRMS and Tandem Quad data from liver samples

Oligonucleotide Analysis using OligoWorks SPE Kits

The quality and safety of pharmaceutical products are the top concerns of regulators. In recent years, regulatory agencies and pharmacopeia&#39;s have strengthened their position on preventing drug adulteration in both active pharmaceutical ingredients (API) and excipients by enacting new regulations and developing new documentary and reference standards.
<ul>
<li>In May’23, USFDA released ‘Guidance for Industry’ mentioning about quantitative testing of DEG and EG levels for representative samples of each shipment of each lot before use in product manufacturing by gas chromatography (GC) instrument.</li>
<li>Ministry of Commerce &amp; Industry (INDIA) also released notification for amendment in Chapter-30 of Schedule 2 (Export Policy) related to export of Cough Syrups.</li>
<li>WHO is also focusing on targeted quality testing of medicinal syrups imported to Rest of the World &amp; Developing nations to confirm quality &amp; compliance of syrups with respect to DEG &amp; EG levels.</li>
</ul>
Join this webinar to hear IPC, USP and Agilent experts share their views on:
<ol>
<li>Role of Pharmacopeia&#39;s in ensuring Quality of Pharmaceutical products and excipients</li>
<li>Importance of Excipient Quality to Medicine Quality</li>
<li>Understanding of high-risk excipients</li>
<li>Advanced workflows to comply with latest regulatory and Pharmacopeial updates</li>
</ol>
<blockquote>
Presenter: Dr. Tong (Jenny) Liu (Principal Scientist in Global Science and Standards - Excipients, United States Pharmacopeia)
</blockquote>
<blockquote>
Dr. Tong (Jenny) Liu is a Principal Scientist in Global Science and Standards — Excipients at the United States Pharmacopeial (USP). She is currently responsible for the development, update, and harmonization of excipient monographs and excipients-related general chapters under the work plan of the Pharmacopeial Discussion Group (PDG). PDG strives for the harmonization of compendial standards among European Pharmacopeia, Indian Pharmacopeia, Japanese Pharmacopeia, and the United States Pharmacopeia.
</blockquote>
<blockquote>
Dr. Liu has 20+ years of experience in analytical method development and validation for pharmaceutical products. She received her Ph.D. in chemistry from Boston University, Boston, USA. Supported by NIH Fellowship, she performed post-doctoral research in the Department of Chemical Biology, Ernest Mario School of Pharmacy in Rutgers University, New Jersey, USA.
</blockquote>
<blockquote>
Presenter: Mr. Arvind Kumar Sharma (Scientific Assistant, Indian Pharmacopoeia Commission, Ministry of Health &amp; Family Welfare - Government of India)
</blockquote>
<blockquote>
With six years of experience as a Scientific Assistant at Indian Pharmacopoeia Commission, he has played a key role in the current development of Indian Pharmacopoeia Reference Substances (IPRS) and Impurity Reference Substances. He has been engaged in the preparation and updating of draft monographs for publishing in Indian Pharmacopoeia (IP). Additionally, he has played a major role in the development of the latest edition of the National Formulary of India 2021 and has been involved in work related to the Pharmacovigilance Programme of India (PvPI). He holds a a M. Pharmacy in Pharmacology from Sinhgad Institute of Pharmaceutical Sciences, Pune and a B. Pharmacy from the College of Pharmacy, IPS Academy Indore. He has authored several articles published in international journals and organized and represented IPC at various national and international conferences and workshops. He has also participated in joint inspections for registration of manufacturing units and testing laboratories.
</blockquote>
<blockquote>
Presenter: Mr. Praveen Arya (Application Engineer - GC/MS, Agilent Technologies)
</blockquote>
<blockquote>
Praveen Arya, Application Engineer at Agilent technologies, has a commitment and appreciation for Gas-phase residue applications. In 2005, Mr. Praveen Arya completed his M.Sc. in Food Technology . After post-graduation, he served as a Senior Analyst at SGS, Gurgaon- a commercial testing laboratory for 6 years and developed expertise in Residue analysis using sophisticated chromatographic instruments such as LCMS and GCMS. After that, in 2011, He joined Agilent Technologies as an Application Engineer where he supported country-wide GCMS customers for resolving application issues and method development. He has more than 18 years of experience in residue analysis in food and environmental samples using various high end chromatographic and spectrometric techniques (GC, GCMS, GCMS/MS, TDS, Headspace, Purge &amp; trap etc.). His area of specialization includes new analytical method development and validation as per national and international guidelines.
</blockquote>

Agilent: Evolving Landscape on Control of Excipients Quality in Pharmaceutical Products

Evolving Landscape on Control of Excipients Quality in Pharmaceutical Products

PC, USP and Agilent experts share their views on the role of Pharmacopeia's in ensuring Quality of Pharmaceutical products and excipients

Control of Excipients Quality in Pharmaceutical Products

<h3>Biopharma Brilliance Webinar Series:</h3>
Glycan &amp; Sialic Acid Workflows in Biotherapeutic Glycoproteins: Sample Prep to Analysis.
<h4>Session 2: Improved Workflow for Sialic Acid Profiling and Quantitation</h4>
Sialic acid is critical in mediating the effectiveness of therapeutic glycoproteins. Its presence (or absence) on the non-reducing terminal of N- or O-glycans can dramatically affect the pharmacokinetics of the protein, as well as its immunogenicity. Depending on the molecule and the application, terminal sialic acid may reduce the rate of clearance, reduce antibody-dependent cellular cytotoxicity (ADCC) activity, or can be anti-inflammatory. Therefore, it is essential to monitor both the absolute quantity of sialic acid and also the levels of different sialic acid species present in therapeutic glycoproteins.
Join us for an engaging webinar where we discuss a new and improved high-throughput workflow for the preparation, separation, and detection of sialic acids labeled with 1,2-diamino-4,5-methylenedioxybenzene (DMB) using the AdvanceBio Sialic Acid profiling and quantitation kit. 
What will you learn?
<ul>
<li>Quick and easy release of sialic acids from glycoproteins, labeled with fluorescent DMB dye.</li>
<li>Identification of sialic acid species with greater accuracy using a qualitative sialic acid reference panel (SARP) featuring six lyophilized sialic acids.</li>
<li>Absolute quantitation of sialic acids with quantitative NANA (Neu5Ac) and NGNA (Neu5Gc) standards.</li>
<li>Reduction of sample prep time to just 5 hours with no sample dry-down step.</li>
<li>Analysis of proteins with low levels of sialylation at picomolar sensitivity.</li>
</ul>
Join both the session and get certified for Brilliance.
<blockquote>
Presenter: Dr. Rajni Mujoo (Technical Support Specialist, CSD, Agilent Technologies)
</blockquote>
<blockquote>
Dr. Rajni is working with us as Technical Support Specialist in Chemistries and Supplies Division at Agilent Technologies since 2011. She has a Ph.D degree in Food Science from CFTRI, Mysore and Post Doctorate from Department Of Food Science, Michigan State University. She also has four International Presentations &amp; 13 publications in reputed National &amp; International journals to her credit. Rajni has a total work experience of 16 yrs spread across research and Sales building expertise in different Instrument techniques.
</blockquote>
<blockquote>
Presenter: Mr. Shreyas Tribhuvane (Business Development Manager, PL BC, Agilent Technologies)
</blockquote>
<blockquote>
Shreyas has 10 years experience in working closely with biopharma customers in understanding their analytical characterization needs. As a BDM for Biocolumns and Glycan kits his prime responsibility is to work on the Biopharma market needs and communicate with Agilent solutions unit team in order to have apt solutions. He has a hands-on experience on Agilent Glycan sample prep kits and helped customers in setting up these kits for their glycan characterization work.
</blockquote>

Agilent: Biopharma Brilliance - Session 2

Biopharma Brilliance - Session 2

Join us for an engaging webinar where we discuss a new and improved high-throughput workflow for the preparation, separation, and detection of sialic acids.

Christian Rohrer, Director of Sales &amp; Support – EMEA at Tosoh Bioscience GmbH, will present the next edition of Tosoh Tuesday, a webinar series held by Chromatography Experts.
Join Jennifer Knister, Product Specialist MCC Instruments at Tosoh Bioscience, as she explains how multi-column chromatography (MCC) can be used to intensify Protein A chromatography in a continuous mode, increasing productivity threefold or more. Many of the benefits of MCC (reduction of materials, decreased suite time, and higher resin utilization) have been identified and presented in recent Tosoh Tuesday webinars. Jennifer will now provide a detailed analysis that will be helpful for organizations considering whether to invest time and money in transitioning to MCC and debating what MCC format is most advantageous for them. BioSolve modeling software was applied to generate a detailed comparison of the processing times, materials costs, and non-material costs for purification platforms at different titers, with both prepacked and self-packed columns.
After the webinar, ask your questions during the live Q&amp;A session.

Tosoh Bioscience: Tosoh Tuesday - Economic Model of Protein A Multi-Column Chromatography

Tosoh Tuesday - Economic Model of Protein A Multi-Column Chromatography

Multi-column chromatography (MCC) can be used to intensify Protein A chromatography in a continuous mode, increasing productivity threefold or more.